During the meeting, the company intends to align on a path forward with the FDA regarding the issues brought up within the CRL. Additionally, Sesen Bio is also preparing for a separate Clinical Type A meeting with the FDA in order to discuss recommendations specific to the requests for additional data and statistical analyses.